Cinryze "complete response" letter means HAE race is still on
This article was originally published in Pharmaceutical Approvals Monthly
FDA's "complete response" letter to ViroPharma regarding its supplemental Cinryze filing for treatment of acute attacks of hereditary angioedema requests an additional clinical trial, stalling the firm's progress in a race with two other C1 esterase inhibitors to be the first acute HAE treatment approved in the U.S. ViroPharma said June 4 that FDA believes the placebo-controlled trial submitted in support of the sBLA "lacked robustness." Cinryze, which was first to market with a prophylaxis claim, is now in the same boat as CSL Behring's C1 esterase inhibitor Berinert: CSL received a "complete response" letter Dec. 5, 2008 requesting another trial. A filing for the third C1 candidate, Pharming's Rhucin, is expected in September. Pharming said March 31 that it is conducting additional data analyses at FDA's behest
You may also be interested in...
Vacancies Reform Act requires individual in an acting position to step down in order to be nominated to the permanent post but there are exceptions. Andrew von Eschenbach retained acting title during his nomination in 2006.
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.